🕷️ Crawler Inspector

# Adverse Events Associated with Melatonin for the Treatment of Primary or Secondary Sleep Disorders: A Systematic Review CNS Drugs. 2019 Dec;33(12):1167-1186. doi: 10.1007/s40263-019-00680-w. ### Authors [Frank M C Besag](https://pubmed.ncbi.nlm.nih.gov/?term=Besag+FMC&cauthor_id=31722088) [1](https://pubmed.ncbi.nlm.nih.gov/31722088/#affiliation-1 "East London Foundation NHS Trust, Bedford, UK. fbesag@aol.com.") [2](https://pubmed.ncbi.nlm.nih.gov/31722088/#affiliation-2 "University College London, London, UK. fbesag@aol.com.") [3](https://pubmed.ncbi.nlm.nih.gov/31722088/#affiliation-3 "King's College London, London, UK. fbesag@aol.com.") , [Michael J Vasey](https://pubmed.ncbi.nlm.nih.gov/?term=Vasey+MJ&cauthor_id=31722088) [4](https://pubmed.ncbi.nlm.nih.gov/31722088/#affiliation-4 ", Bedford, UK.") , [Kim S J Lao](https://pubmed.ncbi.nlm.nih.gov/?term=Lao+KSJ&cauthor_id=31722088) [5](https://pubmed.ncbi.nlm.nih.gov/31722088/#affiliation-5 "Department of Pharmacology and Pharmacy, University of Hong Kong, Pok Fu Lam, Hong Kong.") , [Ian C K Wong](https://pubmed.ncbi.nlm.nih.gov/?term=Wong+ICK&cauthor_id=31722088) [6](https://pubmed.ncbi.nlm.nih.gov/31722088/#affiliation-6 "University College London, London, UK.") [5](https://pubmed.ncbi.nlm.nih.gov/31722088/#affiliation-5 "Department of Pharmacology and Pharmacy, University of Hong Kong, Pok Fu Lam, Hong Kong.") ### Affiliations - 1 East London Foundation NHS Trust, Bedford, UK. fbesag@aol.com. - 2 University College London, London, UK. fbesag@aol.com. - 3 King's College London, London, UK. fbesag@aol.com. - 4 , Bedford, UK. - 5 Department of Pharmacology and Pharmacy, University of Hong Kong, Pok Fu Lam, Hong Kong. - 6 University College London, London, UK. - PMID: [31722088](https://pubmed.ncbi.nlm.nih.gov/31722088/) - DOI: [10\.1007/s40263-019-00680-w](https://doi.org/10.1007/s40263-019-00680-w) ## Abstract **Background:** Melatonin is widely available either on prescription for the treatment of sleep disorders or as an over-the-counter dietary supplement. Melatonin has also recently been licensed in the UK for the short-term treatment of jetlag. Little is known about the potential for adverse events (AEs), in particular AEs resulting from long-term use. Concern has been raised over the possible risks of exposure in certain populations including pre-adolescent children and patients with epilepsy or asthma. **Objectives:** The aim of this systematic review was to assess the evidence for AEs associated with short-term and longer-term melatonin treatment for sleep disorders. **Methods:** A literature search of the PubMed/Medline database and Google Scholar was conducted to identify randomised, placebo-controlled trials (RCTs) of exogenous melatonin administered for primary or secondary sleep disorders. Studies were included if they reported on both the types and frequencies of AEs. Studies of pre-term infants, studies of \< 1 week in duration or involving single doses of melatonin and studies in languages other than English were excluded. Findings from open-label studies that raised concerns relating to AE reports in patients were also examined. Studies were assessed for quality of reporting against the Consolidated Standards of Reporting Trials (CONSORT) checklist and for risk of bias against the Cochrane Collaboration risk-of-bias criteria. **Results:** 37 RCTs met criteria for inclusion. Daily melatonin doses ranged from 0.15 mg to 12 mg. Subjects were monitored for up to 29 weeks, but most studies were of much shorter duration (4 weeks or less). The most frequently reported AEs were daytime sleepiness (1.66%), headache (0.74%), other sleep-related AEs (0.74%), dizziness (0.74%) and hypothermia (0.62%). Very few AEs considered to be serious or of clinical significance were reported. These included agitation, fatigue, mood swings, nightmares, skin irritation and palpitations. Most AEs either resolved spontaneously within a few days with no adjustment in melatonin, or immediately upon withdrawal of treatment. Melatonin was generally regarded as safe and well tolerated. Many studies predated publication of the CONSORT checklist and consequently did not conform closely to the guidelines. Similarly, only eight studies were judged 'good' overall with respect to the Cochrane risk-of-bias criteria. Of the remaining papers, 16 were considered 'fair' and 13 'poor' but publication of almost half of the papers preceded that of the earliest version of the guidelines. **Conclusion:** Few, generally mild to moderate, AEs were associated with exogenous melatonin. No AEs that were life threatening or of major clinical significance were identified. The scarcity of evidence from long-term RCTs, however, limits the conclusions regarding the safety of continuous melatonin therapy over extended periods. There are insufficient robust data to allow a meaningful appraisal of concerns that melatonin may result in more clinically significant adverse effects in potentially at-risk populations. Future studies should be designed to comply with appropriate quality standards for RCTs, which most past studies have not. ## Publication types - Systematic Review ## MeSH terms - Humans - Melatonin / adverse effects\* - Melatonin / therapeutic use\* - Randomized Controlled Trials as Topic - Sleep / drug effects\* - Sleep Wake Disorders / drug therapy\* ## Substances - Melatonin

CNS Drugs. 2019 Dec;33(12):1167-1186. doi: 10.1007/s40263-019-00680-w. ### Affiliations - 1 East London Foundation NHS Trust, Bedford, UK. fbesag@aol.com. - 2 University College London, London, UK. fbesag@aol.com. - 3 King's College London, London, UK. fbesag@aol.com. - 4 , Bedford, UK. - 5 Department of Pharmacology and Pharmacy, University of Hong Kong, Pok Fu Lam, Hong Kong. - 6 University College London, London, UK. - PMID: [31722088](https://pubmed.ncbi.nlm.nih.gov/31722088/) - DOI: [10\.1007/s40263-019-00680-w](https://doi.org/10.1007/s40263-019-00680-w) ## Abstract **Background:** Melatonin is widely available either on prescription for the treatment of sleep disorders or as an over-the-counter dietary supplement. Melatonin has also recently been licensed in the UK for the short-term treatment of jetlag. Little is known about the potential for adverse events (AEs), in particular AEs resulting from long-term use. Concern has been raised over the possible risks of exposure in certain populations including pre-adolescent children and patients with epilepsy or asthma. **Objectives:** The aim of this systematic review was to assess the evidence for AEs associated with short-term and longer-term melatonin treatment for sleep disorders. **Methods:** A literature search of the PubMed/Medline database and Google Scholar was conducted to identify randomised, placebo-controlled trials (RCTs) of exogenous melatonin administered for primary or secondary sleep disorders. Studies were included if they reported on both the types and frequencies of AEs. Studies of pre-term infants, studies of \< 1 week in duration or involving single doses of melatonin and studies in languages other than English were excluded. Findings from open-label studies that raised concerns relating to AE reports in patients were also examined. Studies were assessed for quality of reporting against the Consolidated Standards of Reporting Trials (CONSORT) checklist and for risk of bias against the Cochrane Collaboration risk-of-bias criteria. **Results:** 37 RCTs met criteria for inclusion. Daily melatonin doses ranged from 0.15 mg to 12 mg. Subjects were monitored for up to 29 weeks, but most studies were of much shorter duration (4 weeks or less). The most frequently reported AEs were daytime sleepiness (1.66%), headache (0.74%), other sleep-related AEs (0.74%), dizziness (0.74%) and hypothermia (0.62%). Very few AEs considered to be serious or of clinical significance were reported. These included agitation, fatigue, mood swings, nightmares, skin irritation and palpitations. Most AEs either resolved spontaneously within a few days with no adjustment in melatonin, or immediately upon withdrawal of treatment. Melatonin was generally regarded as safe and well tolerated. Many studies predated publication of the CONSORT checklist and consequently did not conform closely to the guidelines. Similarly, only eight studies were judged 'good' overall with respect to the Cochrane risk-of-bias criteria. Of the remaining papers, 16 were considered 'fair' and 13 'poor' but publication of almost half of the papers preceded that of the earliest version of the guidelines. **Conclusion:** Few, generally mild to moderate, AEs were associated with exogenous melatonin. No AEs that were life threatening or of major clinical significance were identified. The scarcity of evidence from long-term RCTs, however, limits the conclusions regarding the safety of continuous melatonin therapy over extended periods. There are insufficient robust data to allow a meaningful appraisal of concerns that melatonin may result in more clinically significant adverse effects in potentially at-risk populations. Future studies should be designed to comply with appropriate quality standards for RCTs, which most past studies have not. ## Publication types - Systematic Review ## MeSH terms - Humans - Melatonin / adverse effects\* - Melatonin / therapeutic use\* - Randomized Controlled Trials as Topic - Sleep / drug effects\* - Sleep Wake Disorders / drug therapy\* ## Substances - Melatonin